Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial

Fanghui Zhao, Ting Wu, Yuemei Hu, Lihui Wei, Mingqiang Li, Weijin Huang, Wen Chen, Shoujie Huang, Qinjing Pan, Xun Zhang,

The Lancet Infectious Diseases · 2022 · 85 citations · 16 references

Concepts

References

16